Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition

Donna M. Wilcock, Amyn Mohammed Rojiani, Arnon Rosenthal, Gil Levkowitz, Sangeetha Subbarao, Jennifer Alamed, David Wilson, Nedda Wilson, Melissa J. Freeman, Marcia N. Gordon, Dave Morgan

Research output: Contribution to journalArticle

248 Citations (Scopus)

Abstract

The role of microglia in the removal of amyloid deposits after systemically administered anti-Aβ antibodies remains unclear. In the current study, we injected Tg2576 APP transgenic mice weekly with an anti-Aβ antibody for 1, 2, or 3 months such that all mice were 22 months at the end of the study. In mice immunized for 3 months, we found an improvement in alternation performance in the Y maze. Histologically, we were able to detect mouse IgG bound to congophilic amyloid deposits in those mice treated with the anti-Aβ antibody but not in those treated with a control antibody. We found that Fcγ receptor expression on microglia was increased after 1 month of treatment, whereas CD45 was increased after 2 months of treatment. Associated with these microglial changes was a reduction in both diffuse and compact amyloid deposits after 2 months of treatment. Interestingly, the microglia markers were reduced to control levels after 3 months of treatment, whereas amyloid levels remained reduced. Serum Aβ levels and anti-Aβ antibody levels were elevated to similar levels at all three survival times in mice given anti-Aβ injections rather than control antibody injections. These data show that the antibody is able to enter the brain and bind to the amyloid deposits, likely opsonizing the Aβ and resulting in Fcγ receptor-mediated phagocytosis. Together with our earlier work, our data argue that all proposed mechanisms of anti-Aβ antibody-mediated amyloid removal can be simultaneously active.

Original languageEnglish (US)
Pages (from-to)6144-6151
Number of pages8
JournalJournal of Neuroscience
Volume24
Issue number27
DOIs
StatePublished - Jul 7 2004

Fingerprint

Passive Immunization
Microglia
Amyloid
Transgenic Mice
Amyloid Plaques
Anti-Idiotypic Antibodies
Fc Receptors
Antibodies
Injections
Therapeutics
Phagocytosis
Immunoglobulin G
Brain
Serum

Keywords

  • Alzheimer's disease
  • Amyloid β
  • Antibody
  • Behavior
  • Immunization
  • Microglia

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. / Wilcock, Donna M.; Rojiani, Amyn Mohammed; Rosenthal, Arnon; Levkowitz, Gil; Subbarao, Sangeetha; Alamed, Jennifer; Wilson, David; Wilson, Nedda; Freeman, Melissa J.; Gordon, Marcia N.; Morgan, Dave.

In: Journal of Neuroscience, Vol. 24, No. 27, 07.07.2004, p. 6144-6151.

Research output: Contribution to journalArticle

Wilcock, DM, Rojiani, AM, Rosenthal, A, Levkowitz, G, Subbarao, S, Alamed, J, Wilson, D, Wilson, N, Freeman, MJ, Gordon, MN & Morgan, D 2004, 'Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition', Journal of Neuroscience, vol. 24, no. 27, pp. 6144-6151. https://doi.org/10.1523/JNEUROSCI.1090-04.2004
Wilcock, Donna M. ; Rojiani, Amyn Mohammed ; Rosenthal, Arnon ; Levkowitz, Gil ; Subbarao, Sangeetha ; Alamed, Jennifer ; Wilson, David ; Wilson, Nedda ; Freeman, Melissa J. ; Gordon, Marcia N. ; Morgan, Dave. / Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. In: Journal of Neuroscience. 2004 ; Vol. 24, No. 27. pp. 6144-6151.
@article{f515bc97dbd845deb8451c3bbea53400,
title = "Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition",
abstract = "The role of microglia in the removal of amyloid deposits after systemically administered anti-Aβ antibodies remains unclear. In the current study, we injected Tg2576 APP transgenic mice weekly with an anti-Aβ antibody for 1, 2, or 3 months such that all mice were 22 months at the end of the study. In mice immunized for 3 months, we found an improvement in alternation performance in the Y maze. Histologically, we were able to detect mouse IgG bound to congophilic amyloid deposits in those mice treated with the anti-Aβ antibody but not in those treated with a control antibody. We found that Fcγ receptor expression on microglia was increased after 1 month of treatment, whereas CD45 was increased after 2 months of treatment. Associated with these microglial changes was a reduction in both diffuse and compact amyloid deposits after 2 months of treatment. Interestingly, the microglia markers were reduced to control levels after 3 months of treatment, whereas amyloid levels remained reduced. Serum Aβ levels and anti-Aβ antibody levels were elevated to similar levels at all three survival times in mice given anti-Aβ injections rather than control antibody injections. These data show that the antibody is able to enter the brain and bind to the amyloid deposits, likely opsonizing the Aβ and resulting in Fcγ receptor-mediated phagocytosis. Together with our earlier work, our data argue that all proposed mechanisms of anti-Aβ antibody-mediated amyloid removal can be simultaneously active.",
keywords = "Alzheimer's disease, Amyloid β, Antibody, Behavior, Immunization, Microglia",
author = "Wilcock, {Donna M.} and Rojiani, {Amyn Mohammed} and Arnon Rosenthal and Gil Levkowitz and Sangeetha Subbarao and Jennifer Alamed and David Wilson and Nedda Wilson and Freeman, {Melissa J.} and Gordon, {Marcia N.} and Dave Morgan",
year = "2004",
month = "7",
day = "7",
doi = "10.1523/JNEUROSCI.1090-04.2004",
language = "English (US)",
volume = "24",
pages = "6144--6151",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "27",

}

TY - JOUR

T1 - Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition

AU - Wilcock, Donna M.

AU - Rojiani, Amyn Mohammed

AU - Rosenthal, Arnon

AU - Levkowitz, Gil

AU - Subbarao, Sangeetha

AU - Alamed, Jennifer

AU - Wilson, David

AU - Wilson, Nedda

AU - Freeman, Melissa J.

AU - Gordon, Marcia N.

AU - Morgan, Dave

PY - 2004/7/7

Y1 - 2004/7/7

N2 - The role of microglia in the removal of amyloid deposits after systemically administered anti-Aβ antibodies remains unclear. In the current study, we injected Tg2576 APP transgenic mice weekly with an anti-Aβ antibody for 1, 2, or 3 months such that all mice were 22 months at the end of the study. In mice immunized for 3 months, we found an improvement in alternation performance in the Y maze. Histologically, we were able to detect mouse IgG bound to congophilic amyloid deposits in those mice treated with the anti-Aβ antibody but not in those treated with a control antibody. We found that Fcγ receptor expression on microglia was increased after 1 month of treatment, whereas CD45 was increased after 2 months of treatment. Associated with these microglial changes was a reduction in both diffuse and compact amyloid deposits after 2 months of treatment. Interestingly, the microglia markers were reduced to control levels after 3 months of treatment, whereas amyloid levels remained reduced. Serum Aβ levels and anti-Aβ antibody levels were elevated to similar levels at all three survival times in mice given anti-Aβ injections rather than control antibody injections. These data show that the antibody is able to enter the brain and bind to the amyloid deposits, likely opsonizing the Aβ and resulting in Fcγ receptor-mediated phagocytosis. Together with our earlier work, our data argue that all proposed mechanisms of anti-Aβ antibody-mediated amyloid removal can be simultaneously active.

AB - The role of microglia in the removal of amyloid deposits after systemically administered anti-Aβ antibodies remains unclear. In the current study, we injected Tg2576 APP transgenic mice weekly with an anti-Aβ antibody for 1, 2, or 3 months such that all mice were 22 months at the end of the study. In mice immunized for 3 months, we found an improvement in alternation performance in the Y maze. Histologically, we were able to detect mouse IgG bound to congophilic amyloid deposits in those mice treated with the anti-Aβ antibody but not in those treated with a control antibody. We found that Fcγ receptor expression on microglia was increased after 1 month of treatment, whereas CD45 was increased after 2 months of treatment. Associated with these microglial changes was a reduction in both diffuse and compact amyloid deposits after 2 months of treatment. Interestingly, the microglia markers were reduced to control levels after 3 months of treatment, whereas amyloid levels remained reduced. Serum Aβ levels and anti-Aβ antibody levels were elevated to similar levels at all three survival times in mice given anti-Aβ injections rather than control antibody injections. These data show that the antibody is able to enter the brain and bind to the amyloid deposits, likely opsonizing the Aβ and resulting in Fcγ receptor-mediated phagocytosis. Together with our earlier work, our data argue that all proposed mechanisms of anti-Aβ antibody-mediated amyloid removal can be simultaneously active.

KW - Alzheimer's disease

KW - Amyloid β

KW - Antibody

KW - Behavior

KW - Immunization

KW - Microglia

UR - http://www.scopus.com/inward/record.url?scp=3042839092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042839092&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.1090-04.2004

DO - 10.1523/JNEUROSCI.1090-04.2004

M3 - Article

VL - 24

SP - 6144

EP - 6151

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 27

ER -